The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II study of FOLFOX combined with nab-paclitaxel (FOLFOX-A) in the treatment of metastatic or advanced unresectable gastric, gastroesophageal junction adenocarcinoma: Big Ten Cancer Research Consortium—BTCRC-GI15-015.
 
Al Bowen Benson
Consulting or Advisory Role - Abbvie; Apexigen; Array BioPharma; Artemida Pharma; Boston Scientific; Bristol-Myers Squibb; HalioDx; Janssen Oncology; Merck Sharp & Dohme; Mirati Therapeutics; Natera; Pfizer; Samsung Bioepis; Therabionic; Xencor
Research Funding - Amgen (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Elevar Therapeutics (Inst); Infinity Pharmaceuticals (Inst); ITM Solucin (Inst); MedImmune (Inst); Merck Sharp & Dohme (Inst); Rafael Pharmaceuticals (Inst); st pharm (Inst); SynCoreBio (Inst); Taiho Pharmaceutical (Inst); Tyme Inc (Inst); Xencor (Inst)
 
Masha Kocherginsky
Patents, Royalties, Other Intellectual Property - Royalties - co-inventor on Patent 9149485, "Methods and compositions related to glucocorticoid receptor antagonists and breast cancer".
 
Pashtoon Murtaza Kasi
Consulting or Advisory Role - AstraZeneca; Axiom Healthcare Strategies; Bayer; Boston Healthcare Associates; Delcath Systems; Foundation Medicine; Inflecton Point Biomedical Advisors; Ipsen (Inst); Lilly; MSD Oncology; Natera; QED Therapeutics; Taiho Pharmaceutical (Inst); Tempus
Research Funding - Advanced Accelerator Applications (Inst); Array BioPharma (Inst); Boston Scientific (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Tersera (Inst)
Travel, Accommodations, Expenses - AstraZeneca
 
Nataliya Volodymyrivna Uboha
Stock and Other Ownership Interests - Exact Sciences (I); Natera (I)
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Gerson Lehrman Group; Guidepoint Global; Incyte; ipsen; LEK; Lilly; Lilly; M3; QED Therapeutics; Taiho Pharmaceutical; Taiho Pharmaceutical
Research Funding - EMD Serono (Inst); ipsen (Inst); Lilly (Inst); Taiho Pharmaceutical (Inst)
 
Emil Lou
Honoraria - Boston Scientific; Daiichi Sankyo/UCB Japan (Inst); GlaxoSmithKline; Novocure
Consulting or Advisory Role - Boston Scientific; Novocure; Novocure; Novocure; Novocure
Research Funding - Intima; Novocure
Travel, Accommodations, Expenses - GlaxoSmithKline
(OPTIONAL) Uncompensated Relationships - Caris Life Sciences; Minnetronix Medical; NomoCan
 
Yolande Chen
No Relationships to Disclose
 
Howard S. Hochster
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Elion Oncology; Genentech; Merck
 
Sheetal Mehta Kircher
Stock and Other Ownership Interests - Abbott/AbbVie; Penrose
 
Mary Frances Mulcahy
Honoraria - Boston Scientific
Consulting or Advisory Role - Boston Scientific
Research Funding - BTG